Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 (NF1-QDV)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main objective of the study is to investigate the determinants of the quality of life in children and adults with Neurofibromatosis type 1 (NF1) and more particularly the specific impact of neuropsychological deficits. In fact, cognitive impairment is currently considered as one of the most pervasive features of this genetic disorder but its relationship with the worsening of quality of life found in this population has not been directly investigated to date.
Secondary objectives of this study are (i) to compare neuropsychological and quality of life measures between patients and healthy controls matched by age, gender and education level, (ii) to contrast neuropsychological deficits incidence between patients and controls, and (iii) to differentiate NF1 children's self versus hetero-assessment of quality of life.
The main hypothesis of this study is that the neuropsychological impairment classically identified in this clinical population will be associated to the quality of life's worsening both in children and adults.
| Condition | Intervention |
|---|---|
|
Neurofibromatosis Type 1 |
Other: Neuropsychological examination and quality of life measures |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 |
- Quality of life as measured by the questionnaires used in children and adults [ Time Frame: at day 0 for adults; at 4 weeks for children ] [ Designated as safety issue: No ]Several domains in relation with quality of life (self perception, well-being, social life, emotions, etc.)
- Scores obtained from neuropsychological tests (composite measure) [ Time Frame: at day 0 and 2 weeks for adults; at day 0, 2 weeks and 4 weeks for children ] [ Designated as safety issue: No ]The neuropsychological tests used in this study evaluate different domains: language, visuoperceptive and visuomotor abilities, memory, attention, executive function and intelligence skills.
| Estimated Enrollment: | 300 |
| Study Start Date: | May 2013 |
| Estimated Primary Completion Date: | September 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Patients with NF1 | Other: Neuropsychological examination and quality of life measures |
| Healthy controls | Other: Neuropsychological examination and quality of life measures |
Detailed Description:
The study cohort will consist of 150 patients with NF1 (100 adults and 50 children) recruited from the Neurofibromatosis Clinic at the University Hospital in Nantes and Créteil (France). A sample of 150 healthy controls (100 adults and 50 children) will also be recruited from sport and leisure clubs to serve as a normally developing control group.
The protocol assessment includes a standard and thorough neuropsychological examination specific to children and adults, to investigate the different aspects of cognitive domains: language, visuoperceptive and visuomotor abilities, memory, attention, executive function and intelligence skills. Quality of life is measured by a questionnaire specifically adapted to children and adults.
Other factors linked to the NF1 disease (familial or sporadic form, severity and visibility) and to demographic characteristics (sex, age, education level) will be taken into account to study their respective impact on quality of life, as compared with neuropsychological measures.
Eligibility| Ages Eligible for Study: | 8 Years to 59 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria for Patients :
- NF1 diagnosis following National Institutes of Health criteria (1988)
- Age: 8-12 years for children, 18-59 years for adults
- Signed informed written consent (parent and patient for children, patient for adults)
- French speaking
- Resident in France
Inclusion Criteria for Healthy controls:
- Absence of NF1 diagnosis, learning disabilities, intellectual precocity
- Age: 8-12 years for children, 18-59 years for adults
- Signed informed written consent (parent and healthy control for children, healthy control for adults)
- French speaking
- Resident in France
Exclusion Criteria:
- Uncorrectable hearing of visual impairment
- History of psychiatric illness
- Neuropsychological investigation in the last 6 months
- Insufficient language usage
- Any other known history of central nervous system pathology or neuropathological complications of NF1
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01851135
| Contact: Arnaud Roy, PhD | 33 (0) 687491950 | arnaud.roy@univ-angers.fr |
| France | |
| Assistance Publique - Hôpitaux de Paris (Hôpital Henri Mondor) | Recruiting |
| Créteil, France, 94010 | |
| Principal Investigator: Pierre Wolkenstein, MD, PhD | |
| Centre Hospitalier Universitaire de Nantes | Recruiting |
| Nantes, France, 44093 | |
| Contact: Sébastien Barbarot, MD | |
| Principal Investigator: Sébastien Barbarot, MD | |
| Principal Investigator: | Sébastien Barbarot, MD | Nantes University Hospital |
More Information
No publications provided
| Responsible Party: | Nantes University Hospital |
| ClinicalTrials.gov Identifier: | NCT01851135 History of Changes |
| Other Study ID Numbers: | RC12_0130 |
| Study First Received: | April 24, 2013 |
| Last Updated: | June 6, 2014 |
| Health Authority: | France: Agence Nationale de Sécurité du Médicament et des produits de santé |
Keywords provided by Nantes University Hospital:
|
Quality of life Neuropsychological disorders Neurofibromatosis type 1 |
Additional relevant MeSH terms:
|
Neurofibromatoses Neurofibromatosis 1 Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Neoplasms Neoplasms by Histologic Type Neoplasms, Nerve Tissue Neoplastic Syndromes, Hereditary |
Nerve Sheath Neoplasms Nervous System Diseases Neurocutaneous Syndromes Neurodegenerative Diseases Neurofibroma Neuromuscular Diseases Peripheral Nervous System Diseases |
ClinicalTrials.gov processed this record on February 25, 2015